clinical trial · NCT07550374
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
iRegene Therapeutics Co., Ltd.·phase1·not yet recruiting·n = 10
Parkinson's Disease (PD)NouvNeu001 injection
brief summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have previously undergone deep brain stimulation or deep brain nucleus lesioning surgery.
started
May 1, 2026
primary completion
Apr 1, 2028
completion
Jul 1, 2031
last updated
Apr 24, 2026
official title
Phase I Clinical Study to Evaluate the Safety and Efficacy of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol